Loading clinical trials...
Loading clinical trials...
Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis
Conditions
Interventions
Andrographolides
placebo
Locations
1
Chile
Multiple Sclerosis Centre, Pontificia Universidad Catolica de Chile
Santiago, Santiago Metropolitan, Chile
Start Date
September 1, 2014
Primary Completion Date
November 1, 2016
Completion Date
April 1, 2017
Last Updated
October 27, 2014
NCT06276634
NCT07426991
NCT06138132
NCT06390930
NCT06413602
NCT05893225
Lead Sponsor
Innobioscience SpA
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions